Results from the Phase III NRG Oncology NRG-GU003 clinical trial comparing hypofractioned post-prostatectomy radiotherapy (HYPORT) to conventionally fractioned post-prostatectomy radiotherapy (COPORT) determined that HYPORT was non-inferior to COPORT in terms of late gastrointestinal (GI) or genitourinary (GU) toxicity for patients primarily...
Hypofractioned post-prostatectomy radiotherapy new acceptable practice standard based on NRG Oncology trial findings retrieved 18 March 2024 from https://medicalxpress.com/news/2024-03-hypofractioned-prostatectomy-radiotherapy-standard-based.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Nov 4, 2022Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
日本 最新ニュース, 日本 見出し
Similar News:他のニュース ソースから収集した、これに似たニュース記事を読むこともできます。
High quality ASTERAND® accredited human oncology tissues for drug discoveryHuman oncology tissues from BioIVT are a high-quality resource to facilitate drug discovery.
続きを読む »
Novel oral hormone therapy shows promising results for prostate cancer treatment with radiation therapyA study led by Daniel Spratt, M.D., Vincent K. Smith Chair in Radiation Oncology at University Hospitals Seidman Cancer Center demonstrates the safety and efficacy of a novel oral hormone therapy, relugolix, in conjunction with radiation therapy for treating men with localized and advanced prostate cancer. This work is published in JAMA Oncology.
続きを読む »
AI model developed by SOPHiA GENETICS and UroCCR predicts post-operative outcomes in kidney cancer studySOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, and the French Kidney Cancer Research Network collaborated on a study using a multimodal algorithm to help predict post-operative outcomes for those facing renal cell carcinoma, with the results recently published in npj Precision Oncology.
続きを読む »
Relugolix and radiation therapy may be a safe, effective combination for treating prostate cancerA high impact study led by Daniel Spratt, M.D., Vincent K. Smith Chair in Radiation Oncology at University Hospitals Seidman Cancer Center demonstrates the safety and efficacy of a novel oral hormone therapy, relugolix, in conjunction with radiation therapy for treating men with localized and advanced prostate cancer.
続きを読む »
New AI-based, non-invasive diagnostic tool enables accurate brain tumor diagnosis, surpassing current methodsJointly developed by investigators of the Vall d'Hebron Institute of Oncology's (VHIO) Radiomics Group and the Bellvitge University Hospital's Neuroradiology Unit, the Diagnosis in Susceptibility Contrast Enhancing Regions for Neuroncology (DISCERN) is an open-access deep learning tool based on the training of patterns using artificial...
続きを読む »
Hidden Treasures: BBC Radio celebrates rediscovery of historic dramas, including plays by Pinter and PotterOver 1,000 radio plays have been returned to the BBC Archives by the Radio Circle
続きを読む »